Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a

G W Dorn, R M Burch, P J Kochel

    Biochemical Pharmacology
    |June 15, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction: Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction.

    Cell death & disease·2021
    Same author

    Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction.

    Cell death & disease·2016
    Same author

    Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome.

    Free radical biology & medicine·2014
    Same author

    Mitochondrial G protein coupled receptor kinase 2 regulates proinflammatory responses in macrophages.

    FEBS letters·2013
    Same author

    Thromboxane-A(2)/prostaglandin-H(2) receptors Characterization and antagonism.

    Trends in cardiovascular medicine·2011
    Same author

    Cardiac reanimation: targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L.

    Oncogene·2009

    Human platelets release a protein that inhibits thromboxane A2 (TXA2)/prostaglandin H2 (PGH2) receptor agonists, affecting platelet aggregation. This protein may regulate responses to these key aggregatory stimuli.

    Area of Science:

    • Biochemistry
    • Cell Biology
    • Pharmacology

    Background:

    • Platelets mediate aggregation via receptors for thromboxane A2 (TXA2) and prostaglandin H2 (PGH2).
    • Previous studies indicated reduced TXA2/PGH2 mimetic affinities in platelet membranes compared to intact platelets.

    Purpose of the Study:

    • To investigate if platelet lysis releases a substance that decreases TXA2/PGH2 receptor affinity for agonists.
    • To characterize the nature and effect of this substance on receptor binding and platelet aggregation.

    Main Methods:

    • Displacement of a radiolabeled TXA2/PGH2 antagonist ([125I]PTA-OH) from intact platelets using mimetics and antagonists, in the presence and absence of platelet sonicate supernatant.
    • Assessing the effect of supernatant treatment on agonist-induced platelet aggregation.

    Related Experiment Videos

  • Gel filtration chromatography to isolate the active component in the supernatant.

    • Main Results:

    • The supernatant significantly increased IC50 values for TXA2/PGH2 mimetics (U46619, SQ26655, ONO11113), indicating reduced agonist affinity.
    • This effect was abolished by boiling or trypsin treatment, suggesting a protein nature.
    • The supernatant did not alter the binding of a TXA2/PGH2 antagonist (SQ29548) or receptor parameters (Kd, Bmax).
    • Platelet pretreatment with supernatant reduced U46619-induced aggregation.
    • A fraction with an approximate molecular weight of 100,000 daltons was identified as responsible for increasing IC50 values.

    Conclusions:

    • Human platelets release a protein that inhibits TXA2/PGH2 agonist binding to their receptor, without affecting antagonist binding.
    • This protein may play a regulatory role in platelet responses to TXA2/PGH2.
    • The findings suggest an endogenous mechanism for modulating platelet activation.